Table 2. Effectiveness of COVID-19 vaccination among participants aged 65 years and older in the primary care/outpatient I-MOVE-COVID-19 vaccine effectiveness study, Europe, December 2020–May 2021.
| Main analysis (Nine study sites) | |||
|---|---|---|---|
| Analysis type and vaccination status | Cases; vaccinated/ controls; vaccinated | Crude VE (95% CI)a | Adjusted VE (95% CI)b |
| At least one dosec | 592; 84 / 4,372; 2,014 | 74 (64–80) | 73 (63–81) |
| One dose onlyd | 560; 52 / 3,224; 866 | 62 (45–74) | 62 (45–74) |
| Completely vaccinatede | 522; 14 / 3037; 679 | 88 (79–94) | 89 (79–94) |
| Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States) vaccine | |||
| At least one dosec | 566; 61 / 3,672; 1327 | 73 (62–80) | 74 (63–82) |
| One dose onlyd | 535; 30 / 2,778; 433 | 60 (38–74) | 61 (39–75) |
| Completely vaccinatede | 519; 14 / 2,857; 512 | 85 (73–92) | 87 (74–93) |
| Vaxzevria (ChAdOx1/nCoV-19, AstraZeneca, Cambridge, United Kingdom) vaccine | |||
| At least one dosec | 523; 18 / 2,810; 465 | 75 (52–87) | 74 (50–86) |
| One dose onlyd | 523; 18 / 2,687; 342 | 68 (41–83) | 68 (39–83) |
| Completely vaccinatede | Sample size too small | NA | NA |
CI: confidence interval; COVID-19: coronavirus disease; NA: not applicable; VE: vaccine effectiveness.
a Adjusted by study site, month of swab taken (due to low numbers December and January were grouped as one category).
b Adjusted by study site, month of swab taken (due to low numbers December and January were grouped as one category), 10-year age group, sex. Due to substantial missing data on chronic conditions from one study site, the estimates were not adjusted by chronic condition.
c First dose of any COVID-19 vaccine received ≥ 14 days before onset.
d One of two recommended doses of COVID-19 vaccine received ≥ 14 days before onset. Excludes Janssen vaccine as it is a 1-dose vaccine.
e Second dose of COVID-19 vaccine received ≥ 14 days before onset, or first dose received ≥ 14 days before onset if Janssen vaccine. Eighteen cases and 465 controls received a second dose of any vaccine <14 days before onset. In the Comirnaty-specific analysis, 17 cases and 381 controls received a second dose of vaccine <14 days before onset.